Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted ...
MarketBeat on MSN

ALX Oncology targets key readouts to advance CD47, EGFR cancer drug programs

Key Points Interested in ALX Oncology Holdings Inc.? Here are five stocks we like better. ALX Oncology expects key data ...

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, today announced the presentations of two studies in ...
EurekAlert!

EGFR inhibitor-linked cytokine storms: study uncovers the trigger

Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...
AASTOCKS.com

HENLIUS (02696.HK): HLX07 International Multi-center Phase 2/3 Clinical Study Completes First Patient Dosing in China

HENLIUS (02696.HK) announced that its self-developed pimurutamab HLX07 (recombinant anti-EGFR humanized monoclonal antibody ...